NCT06978725 A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
| NCT ID | NCT06978725 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Priovant Therapeutics, Inc. |
| Condition | Cutaneous Sarcoidosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2025-04-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 28 participants in total. It began in 2025-04-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Eligibility Criteria
Inclusion Criteria: 1. Adults subjects (18-74) 2. Cutaneous sarcoidosis with characteristic skin biopsy histology 3. A CSAMI activity score ≥ 10 4. Weight \> 40 kg to \< 130 kg with BMI \< 40 kg/m2 . Exclusion Criteria 1. History of * Lymphoproliferative disorder * Active malignancy; * History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06978725 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cutaneous Sarcoidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06978725 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06978725 currently recruiting?
Yes, NCT06978725 is actively recruiting participants. Contact the research team at clinicaltrials@priovant.com for enrollment information.
Where is the NCT06978725 trial being conducted?
This trial is being conducted at San Francisco, United States, Durham, United States, Philadelphia, United States, Madison, United States.
Who is sponsoring the NCT06978725 clinical trial?
NCT06978725 is sponsored by Priovant Therapeutics, Inc.. The trial plans to enroll 28 participants.